Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cytokinetics

38.00
+0.19000.50%
Pre-market: 38.500.5000+1.32%05:42 EDT
Volume:1.19M
Turnover:45.93M
Market Cap:4.50B
PE:-7.22
High:39.73
Open:38.60
Low:37.90
Close:37.81
Loading ...

B. Riley Adjusts Cytokinetics' Price Target to $88 From $92, Keeps Buy Rating

MT Newswires Live
·
05 Feb

Cytokinetics’ Aficamten: Promising Phase III Trials and Market Expansion Justify Buy Rating

TIPRANKS
·
05 Feb

Top Exec Makes Notable Move with Cytokinetics Stock!

TIPRANKS
·
05 Feb

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
05 Feb

Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program

THOMSON REUTERS
·
30 Jan

Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates

Zacks
·
30 Jan

What Are Analysts Talking About Cytokinetics (CYTK)?

Insider Monkey
·
28 Jan

CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study

Zacks
·
24 Jan

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst

Benzinga
·
23 Jan

Stifel Nicolaus Initiates Coverage on Cytokinetics With Buy Rating, $80 Price Target

MT Newswires Live
·
22 Jan

Cytokinetics Initiated at Buy by Stifel

Dow Jones
·
22 Jan

Cytokinetics Inc : Stifel Initiates Coverage With Buy Rating; Target Price $80

THOMSON REUTERS
·
22 Jan

Cytokinetics initiated with a Buy at Stifel

TIPRANKS
·
22 Jan

Cytokinetics Price Target Maintained With a $120.00/Share by HC Wainwright & Co.

Dow Jones
·
22 Jan

Cytokinetics’ Innovative CK-586 Advances Bolster Buy Rating Amid HFpEF Promise

TIPRANKS
·
21 Jan

Cytokinetics announces start of AMBER-HFpEF, Phase 2 trial of CK-586

TIPRANKS
·
21 Jan

Cytokinetics Announces Start of Amber-Hfpef, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction

THOMSON REUTERS
·
21 Jan

Truist Financial Reaffirms Their Buy Rating on Cytokinetics (CYTK)

TIPRANKS
·
14 Jan

Cytokinetics Price Target Maintained With a $120.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Jan

Cytokinetics: Promising Drug Pipeline and Strategic Vision Drive Buy Rating

TIPRANKS
·
14 Jan